United States securities and exchange commission logo

                          August 19, 2022

       Adam Craig, M.D., Ph.D.
       Chief Executive Officer
       CTI BioPharma Corp.
       3101 Western Avenue, Suite 800
       Seattle, WA 98121

                                                        Re: CTI BioPharma Corp.
Statement on Form S-3
                                                            Filed August 17,
                                                            File No. 333-266926

       Dear Dr. Craig:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jason
Drory at 202-551-8342 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Branden C. Berns